1. Home
  2. SPOT vs GILD Comparison

SPOT vs GILD Comparison

Compare SPOT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPOT
  • GILD
  • Stock Information
  • Founded
  • SPOT 2006
  • GILD 1987
  • Country
  • SPOT Luxembourg
  • GILD United States
  • Employees
  • SPOT N/A
  • GILD N/A
  • Industry
  • SPOT Broadcasting
  • GILD Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SPOT Consumer Discretionary
  • GILD Health Care
  • Exchange
  • SPOT Nasdaq
  • GILD Nasdaq
  • Market Cap
  • SPOT 95.1B
  • GILD 113.0B
  • IPO Year
  • SPOT 2018
  • GILD 1992
  • Fundamental
  • Price
  • SPOT $460.27
  • GILD $92.57
  • Analyst Decision
  • SPOT Buy
  • GILD Buy
  • Analyst Count
  • SPOT 29
  • GILD 26
  • Target Price
  • SPOT $422.03
  • GILD $96.71
  • AVG Volume (30 Days)
  • SPOT 3.4M
  • GILD 7.6M
  • Earning Date
  • SPOT 02-04-2025
  • GILD 02-11-2025
  • Dividend Yield
  • SPOT N/A
  • GILD 3.33%
  • EPS Growth
  • SPOT N/A
  • GILD N/A
  • EPS
  • SPOT 3.84
  • GILD 0.10
  • Revenue
  • SPOT $16,843,631,490.00
  • GILD $28,299,000,000.00
  • Revenue This Year
  • SPOT $20.28
  • GILD $6.50
  • Revenue Next Year
  • SPOT $14.65
  • GILD $0.36
  • P/E Ratio
  • SPOT $119.92
  • GILD $915.61
  • Revenue Growth
  • SPOT 18.52
  • GILD 3.31
  • 52 Week Low
  • SPOT $185.37
  • GILD $62.07
  • 52 Week High
  • SPOT $506.47
  • GILD $98.90
  • Technical
  • Relative Strength Index (RSI)
  • SPOT 49.00
  • GILD 54.42
  • Support Level
  • SPOT $446.78
  • GILD $90.27
  • Resistance Level
  • SPOT $490.67
  • GILD $93.59
  • Average True Range (ATR)
  • SPOT 15.60
  • GILD 2.19
  • MACD
  • SPOT -6.91
  • GILD -0.17
  • Stochastic Oscillator
  • SPOT 25.84
  • GILD 62.18

About SPOT Spotify Technology S.A.

Spotify is the leading global music streaming service provider, with over 600 million monthly active users and 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: